Table 3.
Comparisons between the early and non-early recurrence group
| Factors |
Early recurrence, n (%)
|
Non-early recurrence, n (%)
|
P value |
|
|
N
= 98 (24.1%)
|
N
= 309 (75.9%)
|
|
| Age in yr | 0.21 | ||
| <65 | 51 (52.0) | 183 (59.2) | |
| ≥ 65 | 47 (48.0) | 126 (40.8) | |
| Sex | 0.261 | ||
| Male | 59 (60.2) | 166 (53.7) | |
| Female | 39 (39.8) | 143 (46.3) | |
| Tumor size, median in cm | 0.001 | ||
| < 2.5 | 23 (23.5) | 129 (41.7) | |
| ≥ 2.5 | 75 (76.5) | 180 (58.3) | |
| RM | 0.555 | ||
| Negative | 82 (83.7) | 266 (86.1) | |
| Positive | 16 (16.3) | 43 (13.9) | |
| Tumor location | 0.712 | ||
| Head/uncinate | 63 (64.3) | 191 (62.2) | |
| Neck/body/tail | 35 (35.7) | 116 (37.8) | |
| Differentiation | 0.002 | ||
| Well | 9 (9.2) | 51 (16.5) | |
| Moderate | 65 (66.3) | 223 (72.2) | |
| Poor | 22 (22.4) | 32 (10.4) | |
| Preoperative CA 19-9 in U/mL | 0.004 | ||
| Normal | 28 (28.6) | 139 (45.0) | |
| Abnormal | 70 (71.4) | 170 (55.0) | |
| LVi | 0.125 | ||
| No | 57 (58.2) | 206 (66.7) | |
| Yes | 41 (41.8) | 103 (33.3) | |
| PNi | 0.516 | ||
| No | 24 (24.5) | 86 (27.8) | |
| Yes | 74 (75.5) | 223 (72.2) | |
| NLR | 0.768 | ||
| < 2 | 60 (61.2) | 184 (59.5) | |
| ≥ 2 | 38 (38.8) | 125 (40.5) | |
| Adj. CTx. | 0.058 | ||
| No | 45 (45.9) | 109 (35.3) | |
| Yes | 53 (54.1) | 200 (64.7) | |
| Recurrence pattern | 0.121 | ||
| Local | 26 (26.5) | 73 (35.4) | |
| Systemic | 72 (73.5) | 133 (64.6) |
Adj. CTx.: Adjuvant chemotherapy; CA 19-9: Carbohydrate antigen 19-9; LVi: Lymphovascular invasion; N: Total number of patients; NLR: Neutrophil-lymphocyte ratio; PNi: Perineural invasion; RM: Resection margin.